Nanobiotix ADR Dossier
Qualitative Analysis
Business overview
Nanobiotix S.A. is a late-clinical stage biotechnology company headquartered in Paris, France, pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases. The company's core technology is based on physics-based therapeutic approaches, specifically functionalized hafnium oxide nanoparticles designed to be activated by radiotherapy. Its lead product candidate, JNJ-1900 (also known as NBTXR3), is an intratumoral nanoradioenhancer designed to increase the dose of radiotherapy absorbed by tumor cells, thereby destroying the target tumor and priming the immune response without adding burden to patients or healthcare providers. Nanobiotix has established a major global licensing and collaboration agreement with Janssen (Johnson & Johnson) to lead the clinical development and commercialization of JNJ-1900 across multiple solid tumor indications.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the next-wave Curadigm Nanoprimer platform designed to transiently occupy liver clearance pathways, thereby increasing the bioavailability and efficacy of intravenously administered therapeutics (such as RNA-based vaccines and oncolytic viruses) [2.4.1].
Expected impact: Functions as a significant driver of long-term growth beyond the lead NBTXR3 program by enabling external collaborations and a proprietary internal pipeline.
Collaborating with Janssen (Johnson & Johnson) to advance the clinical development of JNJ-1900 (NBTXR3) across head and neck cancer and lung cancer indications.
Expected impact: De-risks development pipelines, reduces operational cash burn, and preserves eligibility for up to $1.77 billion in potential development, regulatory, and sales milestones.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Janssen exclusive worldwide license for JNJ-1900 (NBTXR3), shifting clinical development costs and commercialization responsibilities to J&J while retaining co-development rights.
Terms: Valued up to approximately $2.6 billion in aggregate, including eligibility for $1.77 billion in development, regulatory, and sales milestones for the first programs, plus up to $650 million for additional indications.
Secures non-dilutive capital to extend the company's cash runway and support the development of JNJ-1900 (NBTXR3).
Terms: Up to $71 million in financing, including $50 million received at closing and an additional $21 million expected in Q4 2026, in exchange for a share of future milestone payments and royalties.